OBJECTIVE: This study reports the gynecologic conditions in postmenopausal women (intact uterus on enrollment) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study of tamoxifen and raloxifene (STAR)/P-2 trial. STUDY DESIGN: This study, with a median follow-up period of 81 months, evaluated the incidence rates/risks of gynecologic conditions among women who were treated with tamoxifen and raloxifene. RESULTS: Compared with women who received tamoxifen therapy, women who received raloxifene therapy had a lower incidence of uterine cancer (relative risk, 0.55)/endometrial hyperplasia (relative risk, 0.19), leiomyomas (relative risk, 0.55), ovarian cysts (relative risk, 0.60), and endometrial polyps (relative risk, 0.30) and had fewer procedures performed. Women receiving tamoxifen therapy had more hot flashes (P < .0001), vaginal discharge (P < .0001), and vaginal bleeding (P < .0001). CONCLUSION: Our results suggest that tamoxifen has more of an estrogenic effect on the gynecologic reproductive organs. These effects should be considered in counseling women on options for breast cancer prevention.
OBJECTIVE: This study reports the gynecologic conditions in postmenopausal women (intact uterus on enrollment) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study of tamoxifen and raloxifene (STAR)/P-2 trial. STUDY DESIGN: This study, with a median follow-up period of 81 months, evaluated the incidence rates/risks of gynecologic conditions among women who were treated with tamoxifen and raloxifene. RESULTS: Compared with women who received tamoxifen therapy, women who received raloxifene therapy had a lower incidence of uterine cancer (relative risk, 0.55)/endometrial hyperplasia (relative risk, 0.19), leiomyomas (relative risk, 0.55), ovarian cysts (relative risk, 0.60), and endometrial polyps (relative risk, 0.30) and had fewer procedures performed. Women receiving tamoxifen therapy had more hot flashes (P < .0001), vaginal discharge (P < .0001), and vaginal bleeding (P < .0001). CONCLUSION: Our results suggest that tamoxifen has more of an estrogenic effect on the gynecologic reproductive organs. These effects should be considered in counseling women on options for breast cancer prevention.
Authors: Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark Journal: JAMA Date: 2006-06-05 Impact factor: 56.272
Authors: J P Costantino; M H Gail; D Pee; S Anderson; C K Redmond; J Benichou; H S Wieand Journal: J Natl Cancer Inst Date: 1999-09-15 Impact factor: 13.506
Authors: Eva Chalas; Joseph P Costantino; D Lawrence Wickerham; Norman Wolmark; George C Lewis; Cynthia Bergman; Carolyn D Runowicz Journal: Am J Obstet Gynecol Date: 2005-04 Impact factor: 8.661
Authors: Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark Journal: Cancer Prev Res (Phila) Date: 2010-04-19
Authors: S R Cummings; S Eckert; K A Krueger; D Grady; T J Powles; J A Cauley; L Norton; T Nickelsen; N H Bjarnason; M Morrow; M E Lippman; D Black; J E Glusman; A Costa; V C Jordan Journal: JAMA Date: 1999-06-16 Impact factor: 56.272
Authors: Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings Journal: J Natl Cancer Inst Date: 2004-12-01 Impact factor: 13.506
Authors: B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark Journal: J Natl Cancer Inst Date: 1998-09-16 Impact factor: 13.506
Authors: Jason D Wright; Vrunda B Desai; Ling Chen; William M Burke; Ana I Tergas; June Y Hou; Melissa Accordino; Cande V Ananth; Alfred I Neugut; Dawn L Hershman Journal: Am J Obstet Gynecol Date: 2017-03-21 Impact factor: 8.661
Authors: Michael E Jones; Flora E van Leeuwen; Wilhelmina E Hoogendoorn; Marian Je Mourits; Harry Hollema; Hester van Boven; Michael F Press; Leslie Bernstein; Anthony J Swerdlow Journal: Breast Cancer Res Date: 2012-06-12 Impact factor: 6.466